• Search
  • Helpdesk
  • Sales contact

Tackling the specificities of NASH/MASH clinical trials

Last updated: May 7, 2025

Integrating PROs into studies on MASH, also known as NASH, is crucial. 
MASH is a debilitating chronic illness that significantly impairs patients’ quality of life, affecting their daily routines, work, and mobility.

  • Patient-centric appraisals are needed in the quest for treatments
  • Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients’ concerns


At Kayentis, we have the full capability to run your MASH studies successfully:

  • We have extensive experience in MASH and hepatic disorders research
  • We offer an enhanced patient-centric eCOA data entry
  • We are a key partner to biotech and big pharma companies
 
Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

ACDM 2026

MAR 15-17 2026 • Berlin, Germany
Booth #22 ACDM26 15-17 March 2026

C-PATH 2026

APR 16-17 2026 • Washington, D.C. USA

2026 Precision in Clinical Trials

APR 30 - MAY 1 2026 • Boston, MA, USA
Booth #3 Precision In Clinical Trials Summit | April 30 - May 1 - Boston

OCT Europe 2026

MAY 6-7 2026 • Barcelona, Spain
Booth #59 16th Annual Outsourcing in Clinical Trials Europe 2026 - Arena International

OCT East Coast 2026

MAY 12-13 2026 • New Brunswick, NJ, USA
Booth #7 17th Annual Outsourcing in Clinical Trials East Coast 2026 - Arena International

Patients as Partners 2026

MAY 19-20 2026 • London, UK
Patients as Partners EU

PCMG 2026

JUNE 16-17 2026 • Berlin, Germany
Register For PCMG26 Updates - PCMG 2026 Annual Assembly